mirodenafil

Known as: 5-ethyl-2-(5-((4-(2-hydroxyethyl)piperazin-1-yl)sulfonyl)-2-propoxyphenyl)-7-propyl-3,5-dihydro-4H-pyrrolo(3,2-d)pyrimidin-4-one, 5-ethyl-2-(5-(4-(2-hydroxyethyl)piperazine-1-sulfonyl)-2-propoxyphenyl)-7-propyl-3,5-dihydro-4H-pyrrolo(3,2-d)pyrimidin-4-one 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2007-2015
051020072015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
INTRODUCTION There is partial evidence to support the use of phophodiesterase-5 inhibitor (PDE5-I) for the treatment of premature… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2010
2010
INTRODUCTION Mirodenafil is a recently developed oral phosphodiesterase type 5 inhibitor, which was observed to significantly… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2010
2010
INTRODUCTION Mirodenafil is a newly developed selective phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2010
2010
The area under the curve (AUC) of mirodenafil after intravenous administration in diabetes mellitus induced by streptozotocin… (More)
  • figure 2
  • table 1
  • table 2
Is this relevant?
2009
2009
The purpose of the present study was to determine sildenafil and a novel PDE-5 inhibitor, mirodenafil in the plasma and corpus… (More)
  • figure 1
  • table 1
  • figure 3
  • table 3
Is this relevant?
2009
2009
The pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous (5, 10, 20 and 50 mg/kg) and… (More)
Is this relevant?
2008
2008
The purpose of this paper is to characterize the cytochrome P450 (CYP) enzymes involved in the metabolism of a new oral… (More)
Is this relevant?
2008
2008
INTRODUCTION Mirodenafil is a newly developed oral phosphodiesterase type 5 inhibitor, currently under investigation as a… (More)
Is this relevant?
2008
2008
Mirodenafil (SK3530) is a new potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5). Recent clinical… (More)
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2007
2007
AbstractAim:To investigate the pharmacokinetic profile and tissue distribution of a novel phosphodiesterase type 5 inhibitor, 5… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?